Bio Rad Laboratories Inc

BIOb

311.350USD

+8.200+2.70%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

Bio Rad Laboratories Inc's Score

Industry at a Glance

Industry Ranking

162 / 210

Overall Ranking

488 / 4617

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

--

Current Rating

--

Target Price

--

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bio Rad Laboratories Inc Highlights

StrengthsRisks

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.05K shares, decreasing 48.56% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

The company's current financial score is 8.24, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 653.00M, representing a year-over-year increase of 0.50%, while its net profit experienced a year-over-year increase of 152.34%.

Score

Industry at a Glance

Previous score

8.24

Change

0



Financials

7.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.91

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.50

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 8.60, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 0.00, which is +Inf% below the recent high of 30.56 and +Inf% above the recent low of -68.58.

Score

Industry at a Glance

Previous score

8.60

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 162/210

No Data

There is no earnings forecast score for this company; the Healthcare Equipment & Supplies industry's average is 7.74.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

There is no price momentum score for this company; the Healthcare Equipment & Supplies industry's average is 6.72.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 0.06%, representing a quarter-over-quarter decrease of 99.94%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Blue Raven Partners, L.P.

4.06M

--

Alice N. Schwartz Revocable Trust

437.51K

--

Schwartz (Norman D)

374.47K

+0.03%

Schwartz (Steven D)

38.24K

+0.15%

Allison (Schwartz)

4.00K

+1.45%

CSS, LLC

1.09K

--

Buckingham Strategic Wealth, LLC

760.00

--

Morgan Stanley Smith Barney LLC

692.00

--

Wells Fargo Advisors

170.00

--

Whittier Trust Company

160.00

--



1

2



The company’s current risk assessment score is 2.00, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.91. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Bio Rad Laboratories Inc

BIOb

3.85 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Artivion Inc

AORT

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Castle Biosciences Inc

CSTL

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment